Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease E-Book

Know about the book -

Cardio-Oncology Practice Manual: A Companion to Braunwald's Heart Disease E-Book is written by Joerg Herrmann and published by Elsevier Health Sciences. It's available with International Standard Book Number or ISBN identification 0323681360 (ISBN 10) and 9780323681360 (ISBN 13).

Today's patients have unique cardiologic needs before, during, and after cancer treatment. Chemotherapies, radiation therapy, and targeted therapies can produce acute side effects or lasting adverse consequences on the heart and circulatory system, making the field of cardio-oncology increasingly important in effective patient care. Cardio-Oncology Practice Manual is a comprehensive, portable guide that provides practical approaches to assessment and management of cardiovascular diseases due to the effects of cardiotoxic agents and treatments. Part of the Braunwald family of renowned cardiology references, it clearly presents clinically relevant aspects of this growing field in one quick, practical reference for a wide range of cardio-oncology providers. - Covers all major cancer therapies, cardiovascular toxicities, and malignancies in a portable, authoritative guide—ideal for cardiologists, cardio-oncologists, general practitioners, internists, medical oncologists, and hematologists. - Offers templated and streamlined content for quick retrieval, with key point summaries for each major section. - Presents cardiac disease entities and specific malignant diseases in a succinct overview format addressing important clinical care aspects. - Features "Central Illustrations" for each topic that visually summarize the chapter and its specific content including algorithms for management of cardiovascular toxicities and one-view overviews of malignancies. - Includes a comprehensive drug guide that provides quick reference to drugs prescribed for cancers with therapeutic indications, manifestations and mechanisms of cardiotoxicity, their risk factors, and risk reduction strategies. - Brings you up to date with new immune therapies, including immune checkpoint inhibitors and CAR T-cell therapies